Initiale PCV-Chemotherapie in der Behandlung von Oligodendrogliomen WHO Grad 2 - verlängertes progressionsfreies Überleben und niedriges Risiko einer histologischen Malignisierung

Authors
Publication date
4 June 2021
Publisher
German Medical Science GMS Publishing House; Düsseldorf
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      German Medical Science

      redirect
      oaioai:oai-gms.dimdi.de:GM21dgnc2...
      Last time updated on 18/06/2021